[1] Belitsos PC. Management of HIV-associated esophageal disease. AIDS Clin Care. 7(3):19-22, 1995.
[2] Bonacini M. Medical management of benign oesophageal disease in patients with human immunodeficiency virus infection. Dig Liver Dis. 33(3):294-300, 2001.
[3] van der Merwe W et al. Proximal oesophageal strictures in a child with HIV disease. S Afr Med J.;93(9):667-8, 2003.
[4] Wilcox CM. Am J Gastroenterol. Esophageal strictures complicating ulcerative esophagitis in patients with AIDS.94 (2):339-43, 1999.
[5] Corti M, Villafañe MF. The compromise of esophagus in HIV/AIDS diseases. Acta Gastroenterol Latinoam.;33(4):211-20, 2003.
[6] Connolly GM et al. Oesophageal symptoms, their causes, treatment, and prognosis in patients with the acquired immunodeficiency syndrome. Gut. 30:1033-9, 1989.
[7] Bonacini M et al. The causes of esophageal symptoms in human immunodeficiency virus infection, a prospective study in 110 patients. Arch Intern Med 151: 1567, 1991.
[8] Mönkemüller KE, Wilcox CM. Diagnosis and treatment of esophagitis in AIDS. Compr Ther; 26(3):163-8, 2000.
[9] Grabar S et al. Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy. HIV Med. 9(4):246-56, 2008.
[10] San-Andrés FJ et al. Incidence of acquired immunodeficiency syndrome-associated opportunistic diseases and the effect of treatment on a cohort of 1115 patients infected with human immunodeficiency virus, 1989-1997. Clin Infect Dis. 36(9):1177-85, 2003.
[11] Chiou CC et al. Esophageal candidiasis in human immunodeficiency virus-infected pediatric patients after the introduction of highly active antiretroviral therapy. Pediatr Infect Dis J.; 21(5):388-92, 2002.
[12] Mocroft A et al. Decline in esophageal candidiasis and use of antimycotics in European patients with HIV.Am J Gastroenterol. 100(7):1446-54, 2005.
[13] Morgan D et al. Survival by AIDS defining condition in rural Uganda. Sex Transm Inf 76:193–197, 2000.
[14] Okeke EN et al: Upper gastrointestinal endoscopic findings in patients with HIV/AIDS at the Jos University Teaching Hospital, Nigeria. Niger J Med 12:202-205, 2003.
[15] Edwards P et al. Esophageal ulceration induced by zidovudine. Ann Intern Med;112(1):65-6, 1990.
[16] Kikendall et al. Pill-induced esophageal injury. Case reports and review of the medical literature. Dig Dis Sci. 28: 174-182, 1983.
[17] Geagea A, Cellier C. Scope of drug-induced, infectious and allergic esophageal injury. Current Opinion in Gastroenterology, 24:496–501, 2008.
[18] Zalar AE et al. Esophageal motility disorders in HIV patients. Dig Dis Sci 48(5):962-7, 2003.
[19] Reevess-Darby VG, Mathias JR, Clench MH. Abnormal gastrointestinal motility in patients with human immunodeficiency syndrome. Gastroenterology 100:A608, 1991.
[20] Barrow PH, Mahomed A, Karlsson KA. HIV and achalasia. AIDS, 19(15) 1709-1710, 2005.
[21] Darouiche RO. Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues. Clin Infect Dis 26: 259-274, 1998.
[22] Dieterich DT, Wilcox CM. Diagnosis and treatment of esophageal diseases associated with HIV infection. Practice Parameters Committee of the American College of Gastroenterology." Am J Gastroenterol 91: 2265-2269, 1996.
[23] AliMohamed F et al. Prevalence of Helicobacter pylori and endoscopic findings in HIV seropositive patients with upper gastrointestinal tract symptoms at Kenyatta National Hospital, Nairobi. East Afr Med J. 2002 May;79(5):226-31.
[24] Wilcox CM, Schwartz DA, Clark WS. Esophageal Ulceration in Human Immunodeficiency Virus Infection: Causes, Response to Therapy, and Long-Term Outcome. Annals of Intern Med. 123(2) 143-149, 1995.
[25] Connolly, op cit.
[26] Morgan D et al. op cit.
[27] Melo NR et al. Oral Candida flora from Brazilian human immunodeficiency virus-infected patients in the highly active antiretroviral therapy era. Mem Inst Oswaldo Cruz 99: 425-431, 2004.
[28] Dodd CI et al. Oral candidiasis in HIV infection: pseudomembranous and erythematous candidiasis show similar rates of progression to AIDS. AIDS 5: 1339-1343, 1991.
[29] McCarthy GM. Host factors associated with HIV-related oral candidiasis. A review. Oral Surgery, Oral Medicine, Oral Pathology, oral radiology, and endodontics 73: 181-186, 1992.
[30] Abid et al. (2005). "Pill-induced esophageal injury: endoscopic features and clinical outcomes." Endoscopy 37: 740-744.
[31] Rajablou, M, Ganz, RA, Batts K. Candida infection presenting as multiple ulcerated masses. Gastrointestinal Endoscopy 65: 164-166, 2003.
[32] Ezzell, JHJ., Bremer J, Adamec TA. Bacterial esophagitis: an often forgotten cause of odynophagia. Am J Gastroenterol 85: 296-298, 1990.
[33] Wilcox, CM, Straub RF, and Clark WS. Prospective evaluation of oropharyngeal findings in human immunodeficiency virus-infected patients with esophageal ulceration. Am. J. Gastroenterol. 90: 1938-1941, 1995.
[34] Wilcox, CM and Schwartz DA. Comparison of two corticosteroid regimens for the treatment of HIV-associated idiopathic esophageal ulcer. Am J Gastroenterol 89: 2163-2167, 1994.
[35] Staras SAS et al. Seroprevalence of cytomegalovirus infection in the United States, 1988–1994." Clin Infect Dis 43: 1143–51, 2006.
[36] Kupperman BD et al. Correlation between CD4+ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. American Journal of Ophthalmology 115:575-582, 1993.
[37] Heiden D et al. Cytomegalovirus retinitis: The neglected disease of the AIDS pandemic. PLoS Medicine 4:1845-1851, 2007.
[38] Ayisi NK et al. T-lymphocytopaenia, opportunistic infections and pathological findings in Ghanaian AIDS patients and their sexual partners. East Afr Med J 74:784-791, 1997.
[39] Madsen M, Nielsen H. Cytomegalovirus esophagitis in a child with human immunodeficiency virus-1 infection presenting as fever of unknown origin and stunted growth.Eur J Pediatr. Sep;165(9):665-6, 2006.
[40] Wilcox CM, Schwartz DA, Clark WS. Op Cit.
[41] Ibid.
[42] Wilcox CM, Saag, MS. Gastrointestinal Complications of HIV Infection: Changing Priorities in the Era of Highly Active Antiretroviral Therapy. Gut published on January 18, 2008.
[43] Siegmund B et al. Esophageal giant ulcer in primary human immunodeficiency virus infection is associated with an infiltration of activated T cells. Scand J Gastroenterol. 42(7):890-5, 2007.
[44] Blitman NM, Ali M. Idiopathic giant esophageal ulcer in an HIV-positive child. Pediatr Radiol. 32(12):907-9, 2002.
[45] Schmassmann-Suhijar D, Schmassmann A. [Aphthous esophagitis as an atypical manifestation of a primary HIV-infection]. Dtsch Med Wochenschr. 126(41):1136-8, 2001.
[46] Wilcox CM et al. Evaluation of idiopathic esophageal ulceration for human immunodeficiency virus. Mod Pathol. 8(5):568-72, 1995.
[47] Houghton JM et al. A role for apoptosis in the pathogenesis of AIDS-related idiopathic esophageal ulcers. J Infect Dis. 175(5):1216-9, 1997.
[48] Wilcox CM, Schwartz DA, Clark WS. Op Cit.
[49] Dieterich DT, Wilcox CM, op cit.
[50] Connolly GM, Gazzard BG. Dysphagia in AIDS - Symptoms causes and value of investigations and treatment. Gut; 29: 723, 1998.
[51] Genereau T et al. Herpes simplex esophagitis in patients with AIDS: report of 34 cases." Clin Infect Dis 22: 926-931, 1996.
[52] Mönkemüller KE, Wilcox CM. op cit.
[53] Jain SK et al. Esophageal tuberculosis: is it so rare? Report of 12 cases and review of the literature. Am J Gastroenterol. 97(2):287-91, 2002.
[54] Ali A. Leishmaniases and HIV/AIDS co-infections: review of common features and management experiences.Ethiop Med J. 40 Suppl 1:37-49, 2002.
[55] Solari R et al. Disseminated histoplasmosis with lesions restricted to the larynx in a patient with AIDS. Report of a case and review of the literature. Rev Iberoam Micol. 2007 Jun;24(2):164-6.
[56] Lim SG et al. Audit of endoscopic surveillance biopsy specimens in HIV positive patients with gastrointestinal symptoms. Gut. 34(10):1429-32, 1993.
[57] Danzig JB et al. Gastrointestinal malignancy in patients with AIDS. Am J Gastroenterol; 86:715-8, 1991.
[58] Friedman SL, Wright TL, Altman DF Gastrointestinal Kaposi's sarcoma in patients with acquired immunodeficiency syndrome: Endoscopic and autopsy findings. 89(1): 102-108, 1985.
[59] Rohrmus, B et al. Outlook in Oral and Cutaneous Kaposi's Sarcoma. The Lancet 356: 2160, 2000.
[60] Shah SB, Kumar KS. Kaposi’s Sarcoma Involving the Gastrointestinal Tract. 6(2), Clinical Gastroenterology and Hepatology. A20, 2008.
[61] Cappell MS, Botros N. Predominantly gastrointestinal symptoms and signs in 11 consecutive AIDS patients with gastrointestinal lymphoma: a multicenter, multiyear study including 763 HIV-seropositive patients. Am J Gastroenterol. 89(4):545-9, 1994.
[62] Corti M et al. [Non-Hodgkin's lymphomas of the digestive tract and anexal glands in AIDS patients.] Acta Gastroenterol Latinoam. 36(4):190-6, 2006.
[63] Wakhisi J. Esophageal cancer in north rift valley of western Kenya. Afr Health Sci; 5(2): 157–163, 2005.
[64] Sumeruk R et al. Oesophageal cancer in three regions of South Africa. S Afr Med J. 1992 Jan 18;81(2):91-3.
[65] Wabinga HR et al. Cancer in Kampala, Uganda, in 1989-91: changes in incidence in the era of AIDS. Int J Cancer. 22;54(1):26-36, 1993.
[66] Blenke EJ et al. Squamous cell carcinoma of the larynx in HIV-positive patients: difficulties in diagnosis and management. Dysphagia. 22(1):68-72. Epub 2006 Nov 1, 2007.
[67] Sitas F et al. The relationship between anti-HPV-16 IgG seropositivity and cancer of the cervix, anogenital organs, oral cavity and pharynx, oesophagus and prostate in a black South African population. Infectious Agents and Cancer 2:6, 2007. Online at: http://www.infectagentscancer.com/content/2/1/6.
[68] Wilcox CM, Saag MS. Gastrointestinal Complications of HIV Infection: Changing Priorities in the Era of Highly Active Antiretroviral Therapy. Gut, 2008.
[69] Wilcox, C. M., Rodgers W. and Lazenby A. (2004). "Prospective comparison of brush cytology, viral culture, and histology for the diagnosis of ulcerative esophagitis in AIDS." Clin Gastroenterol Hepatol 2: 564-567.
[70] Morgan D et al. op cit.
[71] Wilcox CM et al. Fluconazole compared with endoscopy for human immunodeficiency virus-infected patients with esophageal symptoms. Gastroenterology 110:1803-9, 1996.
[72] Dieterich, DT et al. Gastrointestinial Manifestations of HIV Disease, Including the Peritoneum and Mesentery. Textbook of AIDS Medicine. T. C. Merigan, Bartlett JG, Bolognesi D, eds. Baltimore, Williams & Wilkins: 542-546, 1999.
[73] Wilcox CM, Saag MS. Op cit.
[74] Dieterich DT, Wilcox CM. Op cit.
[75] Aste H, Saccomanno S, Munizzi F. Blind pan-esophageal brush cytology. Diagnostic accuracy.Endoscopy. 16(5):165-7, 1984.
[76] Pan QJ et al. Cytologic detection of esophageal squamous cell carcinoma and its precursor lesions using balloon samplers and liquid-based cytology in asymptomatic adults in Llinxian, China. Acta Cytol.;52(1):14-23, 2008.
[77] Wilcox CM, Rodgers W, Lazenby A. Prospective comparison of brush cytology, viral culture, and histology for the diagnosis of ulcerative esophagitis in AIDS. Clin Gastroenterol Hepatol. 2004 Jul;2(7):564-7.
[78] Venter FS, Learmonth G. Esophageal squamous metaplasia: nudging the esophageal carcinoma morphogenetic paradigm. Med Hypotheses. 2002 Apr;58(4):270-5..
[79] Lavy V, Bond C, Wooldridge R. Palliative Care Toolkit: Improving care from the roots up in resource-limited settings. (available online at http://www.helpthehospices.org.uk/international/index.asp?submenu=1&thirdmenu=4)
[80] Mönkemüller KE, Wilcox CM. Op cit.
[81] Eyeson JD at al. Oral manifestations of an HIV positive cohort in the era of highly active anti-retroviral therapy (HAART) in South London. J Oral Pathol Med. 31(3):169-74, 2002.
[82] Ceballos-Salobrena A at al. Oral lesions in HIV/AIDS patients undergoing highly active antiretroviral treatment including protease inhibitors: a new face of oral AIDS? AIDS Patient Care STDS. 14(12):627-35, 2000.
[83] Laine L, Dretler RH, Conteas CN. Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS: a randomized trial. Ann Intern Med 117: 655-660, 1992.
[84] Wilcox, CM et al. A randomized double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. J Infect Dis 176: 227-232, 1997.
[85] Barbaro G et al. Fluconazole versus itraconazole for Candida esophagitis in acquired immunodeficiency syndrome. Gastroenterology 111: 1169-1177, 1996.
[86] Geel J et al. Effect of fluconazole on nevirapine pharmacokinetics. 15th International AIDS Conference, Bangkok, abstract TuPeB4606, 2004.
[87] Uchaipichat V et al. Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data : the effect of fluconazole on zidovudine glucuronidation. British journal of clinical pharmacology. 61(4), 427-439, 2006.
[88] Panomvana Na Ayudhya D et al. Effect of Rifampicin on the Pharmacokinetics of Fluconazole in Patients with AIDS. Clinical Pharmacokinetics, 43(11), 725-732, 2004.
[89] Lopez-Rangel E, Van Allen MI. Prenatal exposure to fluconazole: an identifiable dysmorphic phenotype. Birth Defects Res A Clin Mol Teratol. 73(11):919-23, 2005.
[90] Pursley TJ, et al. Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis.;22(2):336-40, 1996.
[91] Nørgaard M et al. Maternal use of fluconazole and risk of congenital malformations: a Danish population-based cohort study. J Antimicrob Chemother.;62(1):172-6, 2008.
[92] Jick SS Pregnancy outcomes after maternal exposure to fluconazole. Pharmacotherapy. 19(2):221-2, 1999.
[93] Sorensen HT et al. Risk of malformations and other outcomes in children exposed to fluconazole in utero. Br J Clin Pharmacol. 48(2):234-8, 1999.
[94] Ravera M et al. Evaluating diagnosis and treatment of oral and esophageal candidiasis in Ugandan AIDS patients. Emerg Infect Dis 5: 274-277, 1999.
[95] Nyst MJ et al Gentian violet, ketoconazole and nystatin in oropharyngeal and esophageal candidiasis in Zairian AIDS patients. Ann Soc Belg Med Trop 72:45-52, 1999.
[96] Ravera M et al. op cit.
[97] Van Roey J et al. Comparative efficacy of topical therapy with a slow-release mucoadhesive buccal tablet containing miconazole nitrate versus systemic therapy with ketoconazole in HIV-positive patients with oropharyngeal candidiasis. Journal of Acquired Immune Deficiency Syndromes 35: 144-150, 2004.
[98] Smith DE et al. Itraconazole versus ketoconazole in the treatment of oral and oesophageal candidiasis in patients infected with HIV. AIDS 5: 1367-1371, 1991.
[99] Laine L,. Bonacini M. Esophageal disease in HIV infection." Arch Intern Med 154: 1577-1582, 1994.
[100] Darouiche RO op cit.
[101] Dromer F et al. Oral transmission of Candida albicans between partners in HIV-infected couples could contribute to dissemination of fluconazole-resistant isolates. AIDS 11(9): 1095-1101, 1997.
[102] Revankar SG et al. Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clinical Infectious Diseases 26(4): 960-963, 1998
[103] Saag MS et al. Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients. AIDS Res Hum Retroviruses;15(16):1413-7, 1999.
[104] Cartledge JD et al. Itraconazole cyclodextrin solution - effective treatment for HIV-related candidiasis unresponsive to other -azole therapy. J Antimicrob Chemother 38: 1071-1073, 1994.
[105] Wilcox, CM. Esophageal infections, including disorders associated with AIDS. Textbook of Gastroenterology. T. Yamada, Alpers D H, Laine L, Owyang C, Powell D W., Lippincott Williams & Wilkins. 1263-1277, 1999.
[106] Heiden D et al. Op cit.
[107] Wilcox, CM, Straub RF, Schwartz. Cytomegalovirus esophagitis in AIDS: a prospective study of clinical response to ganciclovir therapy, relapse rate and long term outcome. Am J Med 98:169, 1995.
[108] Parente F, Bianchi Porro G. Treatment of cytomegalovirus esophagitis in patients with acquired immunodeficiency syndrome: a randomized controlled study of foscarnet versus ganciclovir; the Italian Cytomegalovirus Study Group. Am J Gastroenterol 93:317, 1998.
[109] Dieterich, DT et al. Foscarnet treatment of cytomegalovirus gastrointestinal infections in acquired immunodeficiency syndrome patients who have failed ganciclovir induction. Am J Gastroenterol 88: 542-548, 1993.
[110] Wilcox CM and Mönkemüller KE. The therapy of gastrointestinal infections associated with the acquired immunodeficiency syndrome." Aliment Pharmocol Ther 11: 425-443, 1997.
[111] Wilcox, CM and Schwartz DA. Op Cit.
[112] Patterson, DL et al. Thalidomide as treatment of refractory apthous ulceration related to human immunodeficiency virus infection. Clin Infect Dis 20: 250-254, 1995.
[113] Jacobson JM et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med;336(21):1487-93, 1997.
[114] Wilcox CM. Op Cit.
[115] Corti M et al. Op cit.
[116] Dezube B op cit.